Kenter, Gemma G <br/><br/>
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Jan 2008 
 - 169-77 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-07-1881  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Cancer Vaccines--immunology<br/>Epitopes, T-Lymphocyte--immunology<br/>Female<br/>Human papillomavirus 16--immunology<br/>Humans<br/>Immunotherapy--methods<br/>Interferon-gamma--biosynthesis<br/>Middle Aged<br/>Oncogene Proteins, Viral--immunology<br/>Papillomavirus E7 Proteins<br/>Papillomavirus Infections--complications<br/>Papillomavirus Vaccines--immunology<br/>Peptides--immunology<br/>Repressor Proteins--immunology<br/>T-Lymphocytes--immunology<br/>Tumor Virus Infections--immunology<br/>Uterine Cervical Neoplasms--therapy